OPKO Health (OPK) Q4 2025 earnings summary

Executive summary

• Exited 2025 with momentum, focusing on diagnostics profitability, advancing ModeX pipeline, leveraging non-dilutive funds, and strengthening the balance sheet.

• Entered a research collaboration with Regeneron Pharmaceuticals for multispecific antibodies, with potential milestone payments exceeding $200 million per program and total collaboration value over $1 billion if successful.

• Completed sale of BioReference's oncology division, streamlining operations and focusing on core clinical labs and 4Kscore Test.

• Advanced multiple clinical programs, including EBV vaccine (Merck), MDX-2001, MDX-2004, and MDX-2003, with new abstracts presented and new trials initiated or planned.

• Expanded partnership with Entera Bio for oral long-acting PTH tablet, accelerating development after favorable data.

Financial highlights

• Q4 2025 consolidated revenue: $148.5 million, down from $183.6 million in Q4 2024, reflecting asset divestitures.

• Q4 2025 net loss: $31.3 million ($0.04/share) vs. Q4 2024 net income of $14 million ($0.01/share), with prior year benefiting from investment gains.

• Diagnostics Q4 2025 revenue: $71.1 million; 4Kscore revenue up 16% year-over-year to $7 million.

• Pharmaceutical Q4 2025 revenue: $77.4 million; product sales up to $43.7 million from $37.4 million year-over-year.

• Pfizer gross profit share reached $12.5 million, a 30% increase year-over-year.

Outlook and guidance

• Q1 2026 revenue expected between $125 million and $140 million; service revenue $71–$75 million.

• Full-year 2026 revenue guidance: $530–$560 million; service revenue $300–$312 million; pharma product revenue $160–$170 million.

• R&D investment for 2026 projected at $125–$135 million, offset by $22–$26 million in BARDA and Regeneron reimbursements.

• Accelerated share repurchases planned, with $112.7 million remaining under authorization.